{"corpus_id":209428960,"paper_sha":"4b3fae2c4fab1b32b3968e8621679a1a4b09ca66","doi":"10.1186/s12881-019-0903-y","arxiv_id":null,"pmid":31864292,"pmcid":"6925483","mag_id":2995175017,"dblp_id":null,"acl_id":null,"title":"Vitamin D receptor ApaI polymorphism associated with progression of liver disease in Vietnamese patients chronically infected with hepatitis B virus","year":2019,"publication_date":"2019-12-01","venue":"BMC Medical Genetics","journal":{"name":"BMC Medical Genetics","pages":null,"volume":"20"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":52,"citation_count":24,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Carcinoma, Hepatocellular","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"pathology","mj":false,"ui":"Q000473"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D006528"},{"d":"Case-Control Studies","mj":false,"ui":"D016022"},{"d":"Deoxyribonucleases, Type II Site-Specific","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D015252"},{"d":"Disease Progression","mj":false,"ui":"D018450"},{"d":"Genotype","mj":false,"ui":"D005838"},{"d":"Hepatitis B virus","mj":false,"qs":[{"q":"isolation & purification","mj":true,"ui":"Q000302"}],"ui":"D006515"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Liver Neoplasms","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"pathology","mj":false,"ui":"Q000473"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D008113"},{"d":"Polymorphism, Single Nucleotide","mj":true,"ui":"D020641"},{"d":"Receptors, Calcitriol","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"}],"ui":"D018167"},{"d":"Vietnam","mj":false,"ui":"D014744"}],"chemicals":[{"n":"Receptors, Calcitriol","ui":"D018167","reg":"0"},{"n":"VDR protein, human","ui":"C579457","reg":"0"},{"n":"Deoxyribonucleases, Type II Site-Specific","ui":"D015252","reg":"EC 3.1.21.4"},{"n":"GGGCCC-specific type II deoxyribonucleases","ui":"C038485","reg":"EC 3.1.21.4"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://bmcmedgenet.biomedcentral.com/track/pdf/10.1186/s12881-019-0903-y","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/4b3fae2c4fab1b32b3968e8621679a1a4b09ca66","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BackgroundVitamin D derivatives and their receptor (VDR) are potent modulators of immune responses in various diseases including malignancies as well as in metabolic and infectious disorders. The impact of vitamin D receptor polymorphisms on clinical outcomes of hepatitis B virus (HBV) infection is not well understood. This study aims to investigate the potential role of VDR polymorphisms (TaqI, FokI, ApaI, and BsmI) in Vietnamese HBV infected patients and to correlate these polymorphisms with the progression of HBV-related liver disease.MethodsFour hundred forty-three HBV infected patients of the three clinically well-defined subgroups chronic hepatitis B (CHB, n = 183), liver cirrhosis (LC, n = 89) and hepatocellular carcinoma (HCC, n = 171) and 238 healthy individuals (HC) were enrolled. VDR polymorphisms were genotyped by DNA sequencing and in-house validated ARMS assays. Logistic regression models were applied in order to determine the association of VDR polymorphisms with manifest HBV infection as well as with progression of related liver diseases mulin different genetic models.ResultsThe VDR ApaI CA genotype was less frequent in HCC than in CHB patients in different genetic models (codominant model, OR = 0.5, 95%CI = 0.3–0.84, P = 0.004; dominant model, OR = 0.46, 95%CI = 0.27–0.76, P = 0.0023). In the recessive model, the genotype ApaI AA was found more frequently among HCC compared to CHB patients (OR = 2.56, 95%CI = 1.01–6.48, P = 0.04). Similarly, the ApaI CA genotype was less frequent in HCC than in non-HCC group codominant model, OR = 0.6, 95%CI = 0.4–0.98, dominant model, P = 0.04 and OR = 0.6, 95%CI = 0.38–0.90, P = 0.017). The ApaI genotypes CA and AA was significantly associated with higher levels of liver enzymes, bilirubin, and HBV DNA (P < 0.05). No association between TaqI, FokI and BsmI polymorphisms and any clinical outcome as well as liver disease progression was found.ConclusionsAmong the four investigated VDR polymorphisms, ApaI is associated with clinical outcome and liver disease progression in Vietnamese HBV infected patients.","claims":[{"public_id":"cl_ffb49b9f6512f9459dae3e5b1589dce4","status":"active","text":"Among the four investigated VDR polymorphisms, ApaI is associated with clinical outcome and liver disease progression in Vietnamese patients chronically infected with hepatitis B virus.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ffb49b9f6512f9459dae3e5b1589dce4"},{"public_id":"cl_8ddaa4a06fbf6aa7438f767758463a91","status":"active","text":"No association is found between TaqI, FokI, or BsmI polymorphisms and clinical outcomes or liver disease progression.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8ddaa4a06fbf6aa7438f767758463a91"},{"public_id":"cl_45e6e1565530124c28c913cb796fc4e7","status":"active","text":"The ApaI CA and AA genotypes are associated with higher liver enzyme levels, bilirubin, and HBV DNA levels.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_45e6e1565530124c28c913cb796fc4e7"},{"public_id":"cl_55c419783f27844be5bcebcc1213891d","status":"active","text":"The ApaI CA genotype is less frequent in hepatocellular carcinoma than in the non-hepatocellular carcinoma group.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_55c419783f27844be5bcebcc1213891d"},{"public_id":"cl_398d33879eea7244c558ffcc79d37ecb","status":"active","text":"The VDR ApaI CA genotype is less frequent in hepatocellular carcinoma than in chronic hepatitis B, and the ApaI AA genotype is more frequent in hepatocellular carcinoma under a recessive model.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_398d33879eea7244c558ffcc79d37ecb"}],"concepts":[{"public_id":"co_004aeb6cbcb872ccc1d8992456f32fcb","status":"active","name":"VDR polymorphisms","description":"Genetic variants in the vitamin D receptor gene evaluated in the study.","types":["genetic markers"],"aliases":["vitamin D receptor polymorphisms"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_004aeb6cbcb872ccc1d8992456f32fcb"},{"public_id":"co_0c3b93a133d4feaf59a95277248b0b66","status":"active","name":"TaqI polymorphism","description":"A vitamin D receptor gene polymorphism at the TaqI restriction site.","types":["genetic polymorphism"],"aliases":["TaqI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0c3b93a133d4feaf59a95277248b0b66"},{"public_id":"co_261f1af3e34ad7085634806aa218c4e9","status":"active","name":"chronic hepatitis B","description":"A chronic hepatitis B virus infection subgroup among the enrolled patients.","types":["disease subgroup"],"aliases":["CHB"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_261f1af3e34ad7085634806aa218c4e9"},{"public_id":"co_6255e16d219e6e754316ba3d6202fdbd","status":"active","name":"VDR ApaI polymorphism","description":"A genetic variation in the vitamin D receptor gene at the ApaI restriction site, examined by genotype in this study.","types":["genetic polymorphism"],"aliases":["ApaI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6255e16d219e6e754316ba3d6202fdbd"},{"public_id":"co_72e7906e9b59aeff8f1c3abaeb623eda","status":"active","name":"liver enzymes","description":"Blood biochemical markers reflecting liver injury or function, measured as clinical outcomes in the patients.","types":["clinical measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_72e7906e9b59aeff8f1c3abaeb623eda"},{"public_id":"co_75b37004faaec86ef24e2e2085d74230","status":"active","name":"HBV DNA","description":"The amount of hepatitis B virus DNA measured as a marker of viral load.","types":["virological measure"],"aliases":["hepatitis B virus DNA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_75b37004faaec86ef24e2e2085d74230"},{"public_id":"co_8edb9034210f53eaa84ea1bb4eb46da2","status":"active","name":"hepatocellular carcinoma","description":"A primary liver cancer used here as a disease subgroup among HBV-infected patients.","types":["disease subgroup"],"aliases":["HCC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8edb9034210f53eaa84ea1bb4eb46da2"},{"public_id":"co_a5e5ab73f2592c290da24e0ed980aa73","status":"active","name":"Vietnamese HBV-infected patients","description":"Patients from Vietnam chronically infected with hepatitis B virus who were enrolled for genetic and clinical association analysis.","types":["study population"],"aliases":["Vietnamese patients chronically infected with hepatitis B virus"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a5e5ab73f2592c290da24e0ed980aa73"},{"public_id":"co_b734cfd59d17970134fcbbd281d39315","status":"active","name":"non-HCC group","description":"The comparison group composed of HBV-infected patients without hepatocellular carcinoma.","types":["comparison group"],"aliases":["non-HCC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b734cfd59d17970134fcbbd281d39315"},{"public_id":"co_d06ee1e9c0101a0f77c7ca79074e8452","status":"active","name":"liver disease progression","description":"Worsening of HBV-related liver disease across clinical stages such as chronic hepatitis B, cirrhosis, and hepatocellular carcinoma.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d06ee1e9c0101a0f77c7ca79074e8452"}],"external_ids":{"DOI":"10.1186/s12881-019-0903-y","ArXiv":null,"PubMed":31864292,"PubMedCentral":"6925483","MAG":2995175017,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://bmcmedgenet.biomedcentral.com/track/pdf/10.1186/s12881-019-0903-y","landing_url":"https://www.semanticscholar.org/paper/4b3fae2c4fab1b32b3968e8621679a1a4b09ca66","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632160,"paper_uid":"c869318b-c4f1-4a20-80d7-af70f76b0701","canonical_identity":{"paper_id":632160,"paper_uid":"c869318b-c4f1-4a20-80d7-af70f76b0701","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/209428960"}